Accueil   Diary - News   All news Alaxia Announces $1.7 Million Award from Cystic Fibrosis Foundation Therapeutics to Start Clinical Development of ALX-009 in Patients

Alaxia Announces $1.7 Million Award from Cystic Fibrosis Foundation Therapeutics to Start Clinical Development of ALX-009 in Patients

Alaxia HDAlaxia SAS announced today an agreement with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), Bethesda, Md., to help support the first-in-patient clinical study of its inhaled antimicrobial drug candidate ALX-009.

 

By delivering two key endogenous antimicrobial substances directly to the lung, ALX-009 is intended to compensate for the defective innate lung defense system of people with cystic fibrosis (CF).

 

ALX-009 already demonstrated in vitro its therapeutic potential against a wide range of bacterial species infecting CF lungs and particularly against clinical isolates with natural or acquired multi-drug resistance.

 

ALX-009 efficacy is not altered by complex structures such as biofilm or sputum present in CF lungs. ALX-009 has the potential to limit emergence of resistance and induction of cross-resistance to available antibiotics thanks to its innovative mode of action. A Phase I clinical trial involving healthy volunteers and CF patients is ongoing.

 

Lire le Communiqué de presse

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree